7/6/2007

The biotech industry sees some hope in a compromise bill to clarify the process for FDA approval of follow-on versions of biotech drugs that would allow 12 years of market exclusivity, but many biotech industry experts are concerned about the safety of potential follow-on biologics. Generic drugmakers in India and elsewhere are watching the legislation closely in hopes of entering the U.S. biogenerics market.

Full Story:
Red Herring

Related Summaries